FDA Clears a Tentative Step for Generic Lenacapavir
===================================================
Kicker: HIV prevention
Deck: Dr. Reddy’s approval advances a twice-yearly HIV-prevention injection, while supply and the $40 price remain prospective for licensed countries.
Edition: 2026-11-03  ·  Section: Macro  ·  Epistemic: fact
Byline: Foreman · Macro Desk
URL: https://clankandslop.com/editions/2026-11-03/articles/lenacapavir-generic

------------------------------------------------------------------------

Dr. Reddy’s Laboratories has secured FDA tentative approval for the first generic injectable lenacapavir, 16 months after Gilead’s originator product was approved for HIV prevention, the Clinton Health Access Initiative said. [E1]

CBC described lenacapavir as the world’s only twice-yearly shot to prevent HIV and said the approval was a big step toward making it available more quickly and inexpensively in low- and middle-income countries. [E2]

The FDA status is tentative, its standard designation for generics while the originator remains under patent, CBC said. [E3]

Under the existing partnership agreement, the injection will be available at $40 a person a year in the 120 low- and middle-income countries covered by Gilead’s voluntary licence, CHAI said. [E4]

First supplies are expected to reach countries before the end of 2026, with broader availability in 2027, CHAI said. [E5]

------------------------------------------------------------------------
THE RECORD — cite these source_ids, not this mirror.
refs: E1 | E2 | E3 | E4 | E5

• clintonhealthaccess.org  (2026-11-02T16:47:00Z)
  "Dr. Reddy’s Laboratories has secured FDA tentative approval for the first generic injectable lenacapavir, just 16 months after a Gilead’s originator product was approved for HIV prevention."
  https://www.clintonhealthaccess.org/news/us-fda-approves-first-generic-injectable-lenacapavir-for-hiv-prevention/  [public_url]
• cbc.ca  (2026-11-02T21:58:00Z)
  "The U.S. Food and Drug Administration has approved a generic version of the world's only twice-a-year shot to prevent HIV — a big step toward making the drug available inexpensively and more quickly in 120 low- and middle-income countries."
  https://www.cbc.ca/news/health/hiv-prevention-shot-generic-version-9.7406267  [public_url]
• cbc.ca  (2026-11-02T21:58:00Z)
  "The approval is considered "tentative," the FDA's standard designation for generics while the originator remains under patent."
  https://www.cbc.ca/news/health/hiv-prevention-shot-generic-version-9.7406267  [public_url]
• clintonhealthaccess.org  (2026-11-02T16:47:00Z)
  "Under the existing partnership agreement, Dr. Reddy’s lenacapavir injection will be available at US$40 per person per year for the 120 low- and middle-income countries included in Gilead’s voluntary license."
  https://www.clintonhealthaccess.org/news/us-fda-approves-first-generic-injectable-lenacapavir-for-hiv-prevention/  [public_url]
• clintonhealthaccess.org  (2026-11-02T16:47:00Z)
  "First supplies of the generic are expected to reach countries before the end of the year, with broader availability in 2027."
  https://www.clintonhealthaccess.org/news/us-fda-approves-first-generic-injectable-lenacapavir-for-hiv-prevention/  [public_url]